J.C. Penney Takes Poison Pill To Dissuade Future Ackmans

Aug 23 2013 | 5:28am ET

J.C. Penney Co. wants to make sure it doesn’t have another William Ackman to deal with.

The retailer, recently embroiled in a very public fight with the Pershing Square Capital Management chief, its largest shareholder, adopted a poison pill that makes it very difficult and expensive to buy more than 10% of the company. The shareholder rights plan will expire in a year and doesn’t cover Pershing Square—as long as any increase in its stake doesn’t violate existing agreements with the company.

The plan will “protect against potential future use of coercive or abusive takeover techniques,” J.C. Penney said.

Pershing Square owns nearly 18% of J.C. Penney. Ackman resigned from the company’s board last week after publicly calling for the replacement of the company’s chairman and interim CEO.

Following his exit, Ackman said he would consider selling off his stake in J.C. Penney. The poison pill makes it unlikely that another activist would be able to take his place.


In Depth

Steinbrugge: Top 10 Hedge Fund Industry Trends for 2017

Jan 3 2017 | 9:03pm ET

Each year, Agecroft Partners' Don Steinbrugge predicts the top hedge fund industry...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

DarcMatter: The Top Trends in Alternative Investments for 2017

Jan 13 2017 | 8:22pm ET

The $7 trillion alternative investments industry is poised for continued growth...

 

From the current issue of

The U.S. Commodity Futures Trading Commission (CFTC) ordered The Goldman Sachs Group Inc., and Goldman, Sachs & Co. to pay a $120 million penalty for attempted manipulation and false reporting of ISDAFIX Benchmark Rates, a global benchmark for interest rate products.